Full Press Release Details
Tau to Participate in March Investor Conferences
February 27, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer
of the innovative alpha-radiation cancer therapy Alpha DaRT , today announced that
CFO Raphi Levy will present at the following investor conferences in March 2025.
| Event: | Investor Summit Event |
| Format: | Presentation |
| Date: | March 11, 2025 |
| Time: | 12:00PM - 12:30PM ET |
| Location: | Virtual |
| Event: | Oppenheimer 35 th Annual Healthcare MedTech & Services Conference |
| Format: | Presentation |
| Date: | March 17, 2025 |
| Time: | 3:20PM - 3:50PM ET |
| Location: | Virtual |
| Event: | Sidoti Small Cap Conference |
| Format: | Presentation |
| Date: | March 19, 2025 |
| Time: | 11:30AM - 12:00PM ET |
| Location: | Virtual |
Mr. Levy will also be available for
1x1 investor meetings at the conferences. Please reach out to your Investor Summit Group, Oppenheimer, and Sidoti representatives to
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli
oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment
of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
Alpha DaRT (Diffusing Alpha-emitters
Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224
impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy
alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims
to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact: